ArticleAMIA ... Annual Symposium proceedings. AMIA Symposium2019
Integrating Clinical Knowledge and Real-World Evidence for Type 2 Diabetes Treatment.
Article in AMIA ... Annual Symposium proceedings. AMIA Symposium, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- A Guideline-Based Decision Tree Achieves Better Glucose Control with Less Hypoglycemia at 3 Months in Chinese Diabetic Patients.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021Article
- Construction of a Non-Mutually Exclusive Decision Tree for Medication Recommendation of Chronic Heart Failure.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical decision support system (CDSS) plays a significant role nowadays and it assists physicians in making decisions for treatment. Generally based on clinical guideline, the principles of the recommendation are provided and may suggest several candidate medications for similar patient group with certain clinical conditions. However, it is challenging to prioritize these candidates and even refine the guideline to a finer level for patient-specific recommendation. Here we propose a method and system to integrate the clinical knowledge and real-world evidence (RWE) for type 2 diabetes treatment, to enable both standardized and personalized medication recommendation. The RWE is generated by medication effectiveness analysis and subgroup analysis. The knowledge model has been verified by clinical experts from the advanced hospitals. The data verification results show that the medications that are consistent with the method recommendation can lead to better clinical outcome in terms of glycemic control, compared to those inconsistent.
Indexed as
Identifiers
32308880PMC7153065W3027933591What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.